Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Safety Board Will Lead To More Advisory Cmte. Meetings – FDA’s Galson

Executive Summary

The advent of FDA's Drug Safety Oversight Board will likely lead to an increase in the number of advisory committee meetings, Center for Drug Evaluation & Research Acting Director Steven Galson said at a meeting of FDA's Science Board April 15

You may also be interested in...



FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals

Postmarketing safety legislation proposed by Senate Finance Committee Chairman Charles Grassley (R-Iowa) and Sen. Chris Dodd (D-Conn.) calls for FDA to establish "expedited procedures" for drug withdrawals

FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals

Postmarketing safety legislation proposed by Senate Finance Committee Chairman Charles Grassley (R-Iowa) and Sen. Chris Dodd (D-Conn.) calls for FDA to establish "expedited procedures" for drug withdrawals

CDER Drug Safety Website Model Includes Elidel; Novartis Objects

Novartis objects to the inclusion of its eczema therapy Elidel in FDA's drug safety website model

Related Content

Topics

UsernamePublicRestriction

Register

PS045703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel